Literature DB >> 21080597

Pharmacogenetics: Clinical response to antiplatelet therapy--how much does genotype count?

Joana Osório.   

Abstract

Year:  2010        PMID： 21080597     DOI： 10.1038/nrcardio.2010.146

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  3 in total

1.  Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.

Authors:  Guillaume Paré; Shamir R Mehta; Salim Yusuf; Sonia S Anand; Stuart J Connolly; Jack Hirsh; Katy Simonsen; Deepak L Bhatt; Keith A A Fox; John W Eikelboom
Journal:  N Engl J Med       Date:  2010-08-29       Impact factor: 91.245

2.  Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Joseph R Walker; Tabassome Simon; Elliott M Antman; Eugene Braunwald; Marc S Sabatine
Journal:  Lancet       Date:  2010-10-16       Impact factor: 79.321

3.  Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

Authors:  Lars Wallentin; Stefan James; Robert F Storey; Martin Armstrong; Bryan J Barratt; Jay Horrow; Steen Husted; Hugo Katus; P Gabriel Steg; Svati H Shah; Richard C Becker
Journal:  Lancet       Date:  2010-10-16       Impact factor: 79.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.